2019
Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals
Tate JP, Sterne JAC, Justice AC. Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30649058, PMCID: PMC6749990, DOI: 10.1097/qad.0000000000002140.Peer-Reviewed Original ResearchConceptsWhite blood countC-statisticBlood countVeterans Aging Cohort Study (VACS) IndexAntiretroviral Therapy Cohort CollaborationDiscrimination of mortalityVACS Index 2.0Antiretroviral therapy initiationCD4 cell countHIV-positive populationHarrell's C-statisticHIV-1 RNAHIV-positive individualsKaplan-Meier plotsCohort CollaborationNadir CD4VAC patientsAntiretroviral therapyCause mortalityCD8 ratioTherapy initiationViral suppressionGeneral healthExcess mortalityLaboratory values
2018
Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation
Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR, investigators F. Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation. Journal Of The International AIDS Society 2018, 21: e25031. PMID: 29334197, PMCID: PMC5810321, DOI: 10.1002/jia2.25031.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioAntiretroviral therapy initiationAIDS mortalityAdjusted hazardCohort CollaborationTherapy initiationAntiretroviral Therapy Cohort CollaborationHIV-1 infectionTreatment-naïve adultsCause of deathMarginal structural modelsART initiationHIV protocolMetabolic deathHazard ratioChronic inflammationRisk factorsCoding CausesSubsequent deathMortalityAIDSCommon pathwayDeathUnmeasured confoundersCause
2017
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4
2016
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Collaboration A. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 2016, 11: e0160460. PMID: 27525413, PMCID: PMC4985160, DOI: 10.1371/journal.pone.0160460.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyLow CD4 countHIV-positive patientsAntiretroviral therapyCD4 countDrug useAntiretroviral Therapy Cohort CollaborationFive-year mortality riskAIDS infectionOlder ageCause-specific mortality rate ratiosNon-AIDS cancerLiver-related mortalityHIV Cohort StudyInjection drug useHIV-1 RNAMortality rate ratiosLiver-related diseasesHigh subsequent mortalityCohort CollaborationLow CD4Prior AIDSCardiovascular mortalityCohort studyPrognostic factors
2015
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Systems A. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal Of Epidemiology 2015, 45: 2038-2049. PMID: 26721599, PMCID: PMC5841611, DOI: 10.1093/ije/dyv295.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCopies/Antiretroviral Therapy Cohort CollaborationTime-varying covariatesTight control groupAdjusted hazard ratioAntiretroviral therapy regimenAIDS Research NetworkIntegrated Clinical SystemsHIV-CAUSAL CollaborationDeath eventsCohort CollaborationHazard ratioTherapy regimenRandomized trialsInverse probability weightingInclusion criteriaMortality analysisClinical treatmentAIDSTherapyDeath analysisDeathTrialsComparative effects
2013
Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug use
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Mugavero M, May M, Harris R, Saag M, Costagliola D, Egger M, Phillips A, Günthard H, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill M, Justice A, D'Arminio Monforte A, Lampe F, Miró J, Staszewski S, Sterne J. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22: 2481-2492. PMID: 19005271, PMCID: PMC2793403, DOI: 10.1097/qad.0b013e328318f130.Peer-Reviewed Original ResearchConceptsAntiretroviral-naïve patientsAntiretroviral therapyLopinavir/ritonavirVirologic failureClinical eventsThird drugART initiationCohort studyAntiretroviral Therapy Cohort CollaborationNaïve HIV-positive patientsHIV-positive patientsObservational cohort studyHIV Cohort StudyART regimenCohort CollaborationNaïve patientsClinical outcomesResidual confoundingClinical practicePatientsInhibitor backboneAbacavirNevirapineTherapyDrugs